A unique collection of 816 metabolism diseases related compounds for high throughput screening (HTS) and high content screening (HCS); Bioactivity and safety confirmed by pre-clinical research and clinical trials and most of them are approved for marketing by FDA, EMA, or CFDA; Covers various major targets including CYP, FAAH, IDO, MAO, etc., in diabetes, obesity, hypertriglyceridemia, hypercholesterolemia, etc.; Effective tool for cell metabolism research; Detailed compound information with structure, target, activity, IC50 value, and biological activity description; Structurally diverse, medicinally active, and cell permeable; NMR and HPLC validated to ensure high purity and quality;
